Evaluation of early prediction using 18F-FDG PET/CT for patients with Iodine-131 refractory differentiated thyroid carcinoma treated with lenvatinib
Not Applicable
- Conditions
- differentiated thyroid carcinoma
- Registration Number
- JPRN-UMIN000022592
- Lead Sponsor
- Department of Medical Oncology, Hokkaido University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Not provided
Exclusion Criteria
1) Medullary or undifferentiated thyroid carcinoma 2) Ever treated with chemotherapy 3) Double cancer 4) Poor physical status 5) Severe complication 6) Fasting blood glucose over 150 mg/dl 7) Brain metastasis or vascular thrombus requiring treatment 8) Inappropriate to perform 18F-FDG PET/CT or CT due to complications 9) Pregnanant or nursing woman 10) Other inappropriate patients judged byinvestigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Receiver Operating Characteristic-Area Under the Curve obtained by 18-FDG PET/CT performed 1 week after initiation of therapy with lenvatinib compared with conventional CT
- Secondary Outcome Measures
Name Time Method